Efficacy and safety of bivalos therapy for postmenopausal osteoporosis. results of russian multicenter trial


Cite item

Full Text

Abstract

Aim. To study effects of one-year therapy with bivalos on mineral bone density (MBD) of the spine in patients with postmenopausal osteoporosis (PMO), effects of bivalos (strontium ranelate) on MBD of the neck of the femur and femur, the levels of bone metabolism markers, quality of life, tolerance of long-term therapy. Material and methods. The study was made of 60 females aged 54-75 years with PMO. MBD was measured with x-ray absorptiometry in the vertebra and proximal femur. Bone markers in blood serum were detected by enzyme immunoassay . Results. After a year of taking bivalos MBD in lumbar vertebra increased by 4.68 ± 4.94%, in the neck of the femur - by 2.0 ± 4.29%, in the proximal femur - by 3.10 ± 3.34%. A significant 19.5% rise in bone alkaline phosphatase and a 16.5% fall in the level of CT were noted showing a stimulating effect of bivalos on bone formation and an inhibiting effect - on bone tissue resorption. Bivalos treatment raised quality of life of the patients: better motility, regress of depression, improved self-appraisal, decreased number of patients with pain in the spine, attenuated pain. The drug was well tolerated, unwanted effects arose in 15% patients, discontinuation of the drug because of toxicity occurred in 5%. Serious side effects were not observed. Conclusion. Strontium ranelate is effective in PMO and is well tolerated.

About the authors

L Ia Rozhinskaia

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

S D Arapova

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

L K Dzeranova

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

N N Molitvoslovova

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

E I Marova

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

A V Il'in

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

L I Benevolenskaia

ГУ Институт ревматологии РАМН, Москва

O A Nikitinskaia

ГУ Институт ревматологии РАМН, Москва

T A Korotkova

ГУ Институт ревматологии РАМН, Москва

N V Toroptsova

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

A V Smirnov

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

N V Demin

ГУ Институт ревматологии РАМН, Москва

S S Rodionova

ФГУ Центральный институт травматологии и ортопедии Росмедтехнологий, Москва

Iu V Buklemeshev

ФГУ Центральный институт травматологии и ортопедии Росмедтехнологий, Москва

A A Shumskiĭ

ФГУ Центральный институт травматологии и ортопедии Росмедтехнологий, Москва

References

  1. Seeman Е. Pathogenesis of bone fragility in women and men. Lancet. 2002; 359: 1841-1850.
  2. Black D. M., Cummings S. R., Karpf D. B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
  3. Boivin G. Y., Chavassieux P. M., Santora А. C. et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. J. Bone 2000; 27: 687-694.
  4. Ettinger В., Black D. M., Mitlak В. H. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treatment with raloxifene: results from a 3-year randomized clinical trial. J. A. M. A. 1999; 282: 637-645.
  5. Arnaud C. D., Zanchetta J. R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001; 344: 1434-1441.
  6. Chavassieux P. M., Arlot M. E., Reda C. et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 1997; 100: 1475-1480.
  7. Meunier P. J., Slosman D. O., Delmas P. D. et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 2002; 87: 2060-2066.
  8. Reginster J. Y., Meunier P. J. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. J. Osteoporos. Int. 2003; 14 (suppl. 3): S56-S65.
  9. Meunier P. J., Roux C., Seeman E. el al. The effects of Strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004; 350: 459-468.
  10. Reginster J. Y., Seeman E., De Vernejoul M. C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 2005; 90: 2816-2822.
  11. Bruyere O., Roux C., Cannata J. B. et al. Associations between increase in bone mineral density and decrease in clinical vertebral fracture incidence during a treatment with strontium ranelate. J. Osteoporos. Int. 2006; 17 (suppl. 1): s8.
  12. Bruyere O., Delmas P. D., Devogelaer J.-P. et al. Relations between increase in femoral neck bone mineral density and decrease in hip fracture incidence during treatment with strontium ranelate. J. Osteoporos. Int. 2006; 17 (suppl. 1): s96.
  13. Meunier P. J., Arlot M. E., Roux J. P. et al. How to rebalance bone turnover in favor of formation. J. Osteoporos. Int. 2006; 17 (suppl. 1): si 14.
  14. Buehler J., Chappuis P., Saffar J. L. et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). J. Bone 2001; 29: 176-179.
  15. Marie P. J. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. J. Osteoporos. Int. 2003; 14 (suppl. 3): S9-S12.
  16. Roux С., Reginster J. Y., Fechtenbaum J. et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Mineral Res. 2006. Online published January, 22.
  17. Reginster J. Y., Sarlet N., Lejeune E., Leonori L. Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. J. Curr. Osteoporos. Rep. 2005; 1: 30-34.
  18. Neer R. M., Arnaud С. D., Zanchetta J. R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001; 344: 1434-1441.
  19. Marquis P. et al. J. Osteoporos. Int. 2005; 16 (3): S54, abstr. P223.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies